177P - Radiologic feature after chemotherapy with anti-VEGF drug for CLM

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Anticancer Agents
Colon and Rectal Cancer
Surgical Oncology
Biological Therapy
Radiation Oncology
Presenter Hitoshi Fujii
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors H. Fujii1, T. Ito2, H. Kin2, I. Mitsunobu2, A. Hayashibe3, H. Ikushima3, Y. Fumimoto3, N. Ogino3
  • 1Surgery, Tondabayashi hospital, 5840082 - Tondabayashi/JP
  • 2Surgery, Rinku General Medical Center, izumisano/JP
  • 3Surgery, Tondabayashi hospital, Tondabayashi/JP



It was reported that novel criteria based on morphologic changes observed on computed tomography in patients with colorectal liver metastasies (CLM) undergoing preoperative chemotherapy and long-term outcomes. The purposes of this study were to confirm the difference of morphologic change to CLM after various chemotherapies.


The study included 38 patients who underwent 5FU-based 1st line regimens with or without molecular target therapy (anti-VEGF drug or anti-EGFR drug) for CLM from 2007 to 2012. They were divided into 3 groups (12 cytotoxic agents alone group, e.g. FOLFOX, XELOX and FOLFIRI, 17 cytotoxic agents with anti-VEGF drug group, and 9 cytotoxic agents with anti-EGFR drug group) retrospectively. All patients underwent routine contrast-enhanced CT at the start of and during chemotherapy. We created a circle to assume 1/4 of the minor axis a radius from the center of a liver tumor, and measured a circular inside CT value of the tumor and an outside CT value and revised the value of erector spinae muscle in a standard. We defined revised inside CT value as Tin, and outside as Tout. Assessment was performed using RECIST.


The rate of response in each group was 33.3%, 58.8%, 66.7%. Two of these 38 patients had a complete response. In comparison with CT before the treatment and the CT 12 weeks after the treatment, eight of 9 responder with anti-VEGF drug showed that the Tin decreased more than 30%, whereas none of 7 non responder with anti-VEGF drug didn't show similar morphologic change (p = 0.0014). The morphologic change that the Tin decreased more than 30% was observed in 88.9 % of response patients with anti-VEGF drug, 25.0% of response patients with cytotoxic agents alone, and 40.0% of response patients with anti-EGFR drug. Though there was no statistically significant difference among the three groups (p = 0.06), these results may in part explain the radiologic feature after chemotherapy with anti-VEGF drug for CLM.


Liver tumor after chemotherapy with anti-VEGF drug may do different morphologic change from the other chemotherapy.

Clinical trial identification


All authors have declared no conflicts of interest.